| pubmed-article:9815666 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C0276535 | lld:lifeskim |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C0033808 | lld:lifeskim |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C0214743 | lld:lifeskim |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:9815666 | lifeskim:mentions | umls-concept:C0085998 | lld:lifeskim |
| pubmed-article:9815666 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9815666 | pubmed:dateCreated | 1999-2-16 | lld:pubmed |
| pubmed-article:9815666 | pubmed:abstractText | AIDS-associated Kaposi's sarcoma (AIDS-KS), the most common malignant complication of human immunodeficiency virus infection, is characterized by neoplastic proliferation of mesenchymal cells. AIDS-KS cells release and respond to an array of cytokines through specific plasma membrane receptors. Specific targeting of potent cytotoxic agents to cell surface receptors/antigens on Kaposi's sarcoma cells may provide effective therapy for this malignancy. We have identified a new target in the form of an interleukin 13 (IL-13) receptor that is overexpressed in the five AIDS-KS cell lines examined. Radiolabeled IL-13 cross-linked to a single protein of about Mr 70,000 in AIDS-KS cells. We utilized a chimeric cytotoxic protein composed of IL-13 and a truncated Pseudomonas exotoxin (IL13-PE38QQR), which was found to be specifically and highly cytotoxic to AIDS-KS cells, as determined by protein synthesis inhibition and clonogenic assays. IL13-PE38QQR demonstrated significant antitumor activity in a human epidermoid carcinoma xenograft model. Normal human umbilical vein-derived endothelial, lymphoid, and bone marrow precursor cells expressed low levels of IL-13 receptors, and IL-13 toxin was not cytotoxic to them. Thus, IL-13 receptor on AIDS-KS cells may represent a novel plasma membrane protein(s) that could be utilized to target therapeutic agents. | lld:pubmed |
| pubmed-article:9815666 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9815666 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815666 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9815666 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9815666 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:9815666 | pubmed:author | pubmed-author:PastanII | lld:pubmed |
| pubmed-article:9815666 | pubmed:author | pubmed-author:GillPP | lld:pubmed |
| pubmed-article:9815666 | pubmed:author | pubmed-author:PuriR KRK | lld:pubmed |
| pubmed-article:9815666 | pubmed:author | pubmed-author:ZhengTT | lld:pubmed |
| pubmed-article:9815666 | pubmed:author | pubmed-author:HusainS RSR | lld:pubmed |
| pubmed-article:9815666 | pubmed:author | pubmed-author:DebinskiWW | lld:pubmed |
| pubmed-article:9815666 | pubmed:author | pubmed-author:ObiriN INI | lld:pubmed |
| pubmed-article:9815666 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9815666 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:9815666 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9815666 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9815666 | pubmed:pagination | 151-6 | lld:pubmed |
| pubmed-article:9815666 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:meshHeading | pubmed-meshheading:9815666-... | lld:pubmed |
| pubmed-article:9815666 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9815666 | pubmed:articleTitle | Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. | lld:pubmed |
| pubmed-article:9815666 | pubmed:affiliation | Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. | lld:pubmed |
| pubmed-article:9815666 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9815666 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815666 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9815666 | lld:pubmed |
